{
    "organizations": [],
    "uuid": "ab6270dca68106acc584d82e70c5d702ea1b0555",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncology-venture-rights-issue-over/brief-oncology-venture-rights-issue-oversubscribed-idUSASM000IPE",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncology Venture Rights Issue Oversubscribed",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:\n* PRESS RELEASE - THE RIGHTS ISSUE OF ONCOLOGY VENTURE IS OVERSUBSCRIBED\n* RIGHTS ISSUE WAS SUBSCRIBED TO ABOUT SEK 59.6 MILLION, RESPONDING TO A SUBSCRIPTION RATE OF ABOUT 133 PERCENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-31T15:49:00.000+02:00",
    "crawled": "2018-02-01T15:48:45.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "oncology",
        "venture",
        "sweden",
        "ab",
        "press",
        "release",
        "right",
        "issue",
        "oncology",
        "venture",
        "oversubscribed",
        "right",
        "issue",
        "subscribed",
        "sek",
        "million",
        "responding",
        "subscription",
        "rate",
        "percent",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}